
BOB CHAMPION CANCER TRUST

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2021

BOB CHAMPION CANCER TRUST

CONTENTS

	Page
Reference and administrative details of the charity, its trustees and advisers	1 - 2
Trustees' report	3 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 - 22

BOB CHAMPION CANCER TRUST

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 30 JUNE 2021

FOUNDER

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)

PRESIDENT

Bob Champion, C.B.E.

MEDICAL ADVISOR

Professor David Dearnaley

VICE PRESIDENTS

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Chris Hughes (appointed April 2021)

Jonjo O'Neill

Greg Rusedski, Esq

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

TRUSTEES

Michael I Cattermole, Esq. (Chairman)

Susie Burrage (appointed July 2021)

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

TRUST OFFICERS

Mrs Lucienne Wilkinson

BOB CHAMPION CANCER TRUST

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
(CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2021**

Charity registered number

1024664

Principal office

Unit D Molasses House
Clove Hitch Quay
Plantation Wharf
London
SW11 3TN

Secretary

Mrs. Lucienne Wilkinson

Chief executive officer

Mrs. Lucienne Wilkinson

Accountants

Ecovis Wingrave Yeats UK Limited
Waverley House
7-12 Noel Street
London
W1F 8GQ

BOB CHAMPION CANCER TRUST

TRUSTEES' REPORT FOR THE YEAR ENDED 30 JUNE 2021

The Trustees present their report and the accounts for the year ended 30th June 2021.

Administrative Details

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year, either in person or via zoom, dependant on Covid 19 restrictions.

Please see page 1 for Trustee details, legal and other administrative detail.

Structure, governance and management

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

Objectives and activities

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate and testis.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust with The University of East Anglia (UEA) opened The Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases.

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donations with the benefit of claiming Gift Aid if applicable. Income is raised from active social media campaigns and appeals plus a full fundraising calendar, although the Covid -19 pandemic continued to have a restrictive effect on the ability to hold in person events. The fundraising team adapted as many events/appeals as possible to online but this presented another set of issues involving existing software and IT restrictions. The calendar has historically been made up of events ranging from cake stalls, coffee mornings and race nights to personal challenges, such as the London Marathon, and Gala Dinners. As many events as possible did take place, working within the government regulations, with the Trust mindful of protecting their supporters, participants, staff and volunteers. This was successfully achieved in relation to the adapted plans set in place to celebrate the 40th Anniversary of Bob Champion and Aldaniti's triumphant win at Aintree in the 1981 Grand National – Bob's 40FOR40 Anniversary Walk.

BOB CHAMPION CANCER TRUST

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2021

Objectives and activities (continued)

The 40FOR40 event saw Bob Champion embark on a sponsored 191 mile walk. 191 miles representing the 191 days of gruelling cancer treatment he underwent from his diagnosis on 24th July 1979 to receiving the 'all clear' 31st January 1980. The distance was covered by 40 smaller walks at memorable stops on route to Findon, Aldaniti's training home, in Sussex. All 40 stops, starting with the iconic Aintree Racecourse and finishing at Findon, were connected to Bob's remarkable life story with each stop representing a year from 1981 to 2021. Members of the public were encouraged to sponsor him and towards the end of the five week journey, as Covid 19 regulations began to lift, members of the public could gain sponsorship to actually join on the day and walk with him. The majority of the 40 memorable stops took place at racehorse training yards that Bob had enjoyed connections to in his career and the mileage for that day (day's length ranged from 7 -14 miles) taken on the gallops and surrounding countryside. Other stops visited included the Royal Marsden Hospital and Institute of Cancer Research in Surrey, the site of the first research centre funded by the Trust, and Aldaniti's grave in Kirdford, Sussex.

The Trust is also involved every year with the Shetland Pony Grand National. The Shetland Pony Grand National is a major part of the London International Horseshow, races are held twice daily during the five days of the show with the grand finale on the final day. Sadly, due to the pandemic, the 2020 show at Olympia was cancelled and the show was moved to Excel in December 2021. Bob Champion is heavily involved during the year, helping the children qualify for the Show, and attends every day during the Show in December. The young jockeys (aged between 9-14 years) once they qualify for the show commit to raise sponsorship for the Trust.

A biennial Carol Concert, Carols and Champagne, is held at Chelsea Old Church in London. Due to the pandemic the 2020 concert was postponed to December 2021. A charity raceday is held annually at Plumpton Racecourse but, sadly, due to Covid -19 this was cancelled as racing was only allowed behind closed doors at that time. An online auction was held in replacement of the day with the event held again person with restricted numbers in October 2021.

Bob Champion took part in an ITV production to raise awareness of male cancers 'The Real Full Monty' which aired in December 2020 and was a huge success and managed to raise donations and increase the Trust's social media profile.

The Trust has produced, since 1988, its own, especially commissioned, double sided Christmas card. The card not only raises funds but spreads awareness of the cause and the work of the Trust. The artist/s is selected each year and kindly donates their time, or only charges for material costs, and skill in support of the Trust.

Bob Champion was awarded a CBE in The Queen's New Year Honours for his charitable works. He attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from a wide league of friends, volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to help cancer sufferers, their family and friends.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2021**

Achievements and performance

Each year in the UK of the 48,000 men, who will be diagnosed with prostate cancer, more than 11,000 can expect to die from their disease. Significant improvements, therefore, also need to be made in the treatment of this disease.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer. This is bad news for sufferers of prostate cancer because cancer genes, once found, can be used to aid treatment and act as targets for new drugs.

A particular problem is the highly variable natural history of prostate cancer causes significant problems in its clinical management. Over-treatment of prostate cancers is a particular concern leading to impotence in a high proportion of cases. This is especially true for PSA screen-detected cancers that are mostly biologically irrelevant and in the absence of treatment would never become life threatening. Conversely, more conservative approaches to disease detection and management may leave potentially aggressive cancers untreated.

Following the recent discovery by the Bob Champion Cancer Trust identifying a new class of prostate cancer, we know that the patients with this new class, named DESNT cancer, sadly have a very poor outcome. Following that breakthrough the Trust is continuing to fund a project aimed at identifying improved clinical markers (biomarkers) which allow radical therapies such as surgery and radiotherapy to be targeted to men with significant cancers, so that the remainder, with biologically unimportant disease, are spared the side-effects of treatment. This project focuses on the use of urine exosomes (small fat covered vesicles given off by cancer cells) to monitor the cancer gene expression. This work forms part of a Global Urine Biomarker initiative, run by Professor Colin Cooper and involving Centres in Canada, USA, UK and Europe, aimed at identifying biomarkers of aggressive prostate cancer.

Professor Cooper, Chair of Cancer Genetics at the University of East Anglia, Associate Dean of Research in the Faculty of Medical Health runs the ICGC Prostate Cancer Project aimed at collecting whole genome DNA sequence from 250 prostate cancer samples including cancers from Shanghai. This is now being expanded to a global initiative called the PanProstate Cancer Group. Professor Cooper is also running a number of Strategic Developments including facilitating translational research between the University and the Norwich Hospital where 5,000 patients are diagnosed with cancer each year including 750 patients with prostate cancer and 10-20 with testicular cancer. These themes form the basis of three projects currently funded by the Trust at UEA.

At the Institute of Cancer Research the Trust's five year grant support in a cancer sequencing project, headed by Professor Ros Eeles, on early on-set prostate cancer – diagnosed at 60 years or less - has been extended for a further two years. This particular study aims to identify targets for personalised therapy and genetic changes in the DNA in order to offer targeted screening to their relatives who harbour these variants.

The Bob Champion post-doctoral fellowship, within Professor Gert Attard team, is divided between the ICR, computational team in the Centre for Evolution and Cancer (CEC) and the University College London Cancer Institute. The work involves whole genome sequencing data from plasma DNA which allows estimation of the amount of tumour material present in a patient's blood. In addition to analysing data from prostate cancer patients participating in several clinical trials, in collaboration with the Royal Marsden Hospital and ICR Urology Unit, which will be extended to patients with bladder or testicular cancer.

BOB CHAMPION CANCER TRUST

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2021

Achievements and performance (continued)

Understandably certain studies were interrupted until early 2021 as scientists and laboratory space was required for Covid-19 research and data analysis.

Publications:- No Presentations took place due to Covid - 19

1. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression. Luca BA, Moulton V, Ellis C, Connell SP, Brewer DS, Cooper CS. *Genes (Basel)*. 2020;11:802. doi: 10.3390/genes11070802.PMID: 32708551
2. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer. Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS. *Prostate*. 2020 ;80(7):547-558. doi: 10.1002/pros.23968.PMID: 32153047
3. Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy
Shea P, Connell, Robert Mills, Hardev Pandha, Richard Morgan, Colin S. Cooper, Jeremy Clark, Daniel S. Brewer, The Movember GAP1 Urine Biomarker Consortium. *Cancers (Basel)* 2021; 13: 2102. doi: 10.3390/cancers13092102 PMID: 8123800
4. The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers. Richard Y. Ball, Ryan Cardenas, Mark S. Winterbone, Marcelino Y. Hanna, Chris Parker, Rachel Hurst, Daniel S. Brewer, Lauren D'Sa, Rob Mills, Colin S. Cooper, Jeremy Clark. *Life (Basel)* 2021; 11: 1172 doi: 10.3390/life11111172, PMCID: 8622091

Financial review

The net incoming resources for the year were £119,556 (2020: £37,675) which include a surplus on fundraising events of £105,388 (2020: £119,689) and dividends received of £45,336 (2020: £50,960). In addition, unrealised gain on investments was £215,043 (2020: £26,401).

The Trustees are satisfied that the charity's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the charity to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

BOB CHAMPION CANCER TRUST

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2021

Plans for the Future

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at The Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

Statement of Trustees' responsibilities

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

The trustees are required to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and the incoming resources and application of resources, including the net income or expenditure, for the year. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Companies Act. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charity's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves.

Approved by order of the members of the board of Trustees on behalf by:

Mike Cattermole

Michael Cattermole
Trustee

2nd April 2022
Tim Fox
Timothy Fox
Trustee

and signed on their

BOB CHAMPION CANCER TRUST

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 30 JUNE 2021

Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the charity')

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 30 June 2021.

This report is made solely to the charity's Trustees, as a body, in accordance with section 145 of the Charities Act 2011 and regulations made under section 154 of that Act. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees, as a body, for our work or for this report.

Responsibilities and Basis of Report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: *Stuart Hinds*

Stuart Hinds
For and on behalf of

Dated: 06 April 2022

ACA

Ecovis Wingrave Yeats UK Limited

Waverley House
7-12 Noel Street
London
W1F 8GQ

BOB CHAMPION CANCER TRUST

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 30 JUNE 2021**

	Note	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income from:				
Donations and legacies	2	39,148	39,148	26,380
Other charitable activities	3	155,918	155,918	217,564
Investments	4	45,337	45,337	50,975
Other income	5	6,444	6,444	1,988
		<u>246,847</u>	<u>246,847</u>	<u>296,907</u>
Total income				
Expenditure on:				
Raising funds		50,530	50,530	97,875
Charitable activities:				
Research grants	6	187,222	187,222	84,225
Support costs	7	91,459	91,459	93,693
Governance	7	13,123	13,123	9,840
		<u>342,334</u>	<u>342,334</u>	<u>285,633</u>
Total expenditure				
Net (expenditure)/income before net gains on investments		(95,487)	(95,487)	11,274
Net gains on investments	10	215,043	215,043	26,401
		<u>119,556</u>	<u>119,556</u>	<u>37,675</u>
Net movement in funds				
Reconciliation of funds:				
Total funds brought forward		1,555,465	1,555,465	1,517,790
Net movement in funds		119,556	119,556	37,675
		<u>1,675,021</u>	<u>1,675,021</u>	<u>1,555,465</u>
Total funds carried forward				

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 11 to 22 form part of these financial statements.

BOB CHAMPION CANCER TRUST

BALANCE SHEET
AS AT 30 JUNE 2021

	Note	2021 £	2020 £
Fixed assets			
Tangible assets	9	2,452	3,268
Investments	10	1,663,792	1,448,749
		<u>1,666,244</u>	<u>1,452,017</u>
Current assets			
Debtors	11	1,328	6,674
Cash at bank and in hand		75,742	138,810
		<u>77,070</u>	<u>145,484</u>
Creditors: amounts falling due within one year	12	(68,293)	(42,036)
Net current assets		<u>8,777</u>	<u>103,448</u>
Total assets less current liabilities		<u>1,675,021</u>	<u>1,555,465</u>
Total net assets		<u>1,675,021</u>	<u>1,555,465</u>
Charity funds			
Restricted funds		-	-
Unrestricted funds		1,675,021	1,555,465
Total funds		<u>1,675,021</u>	<u>1,555,465</u>

The financial statements were approved and authorised for issue by the Trustees on 2.4.22 and signed on their behalf by:

Mike Cattermole
Michael Cattermole
Trustee

Tim Fox
Timothy Fox
Trustee

The notes on pages 11 to 22 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

1.2 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

1.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the Friends is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

1. Accounting policies (continued)

1.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in charitable activities that raise funds.

Charitable activities and Governance costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

1.5 Going concern

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts.

1.6 Government grants

Government grants are accounted for under the accruals model as permitted by the Charities SORP. During the year the Charity has received governmental support through the Coronavirus Job Retention Scheme. The government grants received in the year are of a revenue nature and are recognised in the Statement of Financial Activities in the same period as the related expenditure.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

1. Accounting policies (continued)

1.7 Tangible fixed assets and depreciation

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer equipment	- 25% reducing balance
--------------------	------------------------

1.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

1. Accounting policies (continued)

1.13 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Pensions

The charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the charity to the fund in respect of the Year.

1.15 Critical accounting estimates and areas of judgement

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

1.16 Basis of non-conclusion

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

BOB CHAMPION CANCER TRUST

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2021

2. Income from donations and legacies

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
League of Friends	-	-	10,050
Memorial	34,727	34,727	6,230
Other	4,421	4,421	10,100
Total	39,148	39,148	26,380

In both the current year and prior year all income from donations and legacies was in relation to unrestricted funds.

3. Activities for generating funds

Income from non charitable trading activities

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Shetland Pony Grand National*	-	-	38,258
Tennis tournament*	20	20	414
40for40	100,883	100,883	-
Christmas Season	29,282	29,282	29,251
General fundraising	20,955	20,955	37,809
Plumpton Raceday*	4,778	4,778	111,832
Total	155,918	155,918	217,564

*These events were not able to take place during the year due to the Covid-19 pandemic.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

4. Investment income

	Unrestricted funds 2021 £	Total funds 2021 £	<i>Total funds 2020 £</i>
Listed securities	45,336	45,336	50,960
Bank deposits	1	1	15
Total	<u>45,337</u>	<u>45,337</u>	<u>50,975</u>

In both the current year and prior year all investment income was in relation to unrestricted funds.

5. Other income

	Unrestricted funds 2021 £	Total funds 2021 £	<i>Total funds 2020 £</i>
Government grants - furlough income	6,444	6,444	1,988

BOB CHAMPION CANCER TRUST

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2021

6. Research grants

	Grants to Institutions 2021 £	Total funds 2021 £	Total funds 2020 £
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	92,710	92,710	23,056
Bob Champion Cancer Trust Post Doctoral fellowship grant - ICR and UCL	55,125	55,125	28,030
Professor Colin Cooper grant - UEA	39,387	39,387	33,139
Total	<u>187,222</u>	<u>187,222</u>	<u>84,225</u>

Professor Ros Eeles, Prostate Cancer Sequencing Project at the ICR, commenced in August 2019 at a cost of £282,509 over the three year grant period. Due to Covid-19, this grant was put on hold in the prior year as the ICR focused efforts on research of the virus. However, the grant resumed in the current year.

Dr Marianna Buongiorno was appointed in November 2017 for three years at a cost of £188,000 to hold the position of the Bob Champion Post - doctoral fellowship within Dr Gert Attard's team at the ICR. Dr Gert Attard is Affiliate Team Leader for the Centre for Evolution and Cancer at the ICR and Team Leader of Treatment Resistance Research Group at UCL. Due to Covid-19, this grant was put on hold in the prior year as the ICR has focused efforts on research of the virus. However, the grant resumed during the current year with Dr Marianna Buongiorno being replaced by Dr Mahedi Hassan in the Bob Champion Post Doctoral Fellowship position.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded in January 2020 for two years at a cost of £80,000. Professor Cooper is Professor of Cancer Genetics and Associate Dean of Research at UEA. This grant is due to end in December 2021 and, post year end, in November 2021, this grant was extended. The BCCT will continue to fund the project with Rachel Hurst with funds being taken up to, but no later, than 31st December 2024. It has been agreed that BCCT will pay 75% of the total grant, approximately £50,000 per annum.

Furthermore, prior to the year end in June 2021, a grant extension was offered to support Dan Brewer within Professor Colin Cooper's team on the DESNT project. The grant covers the project for one year at £30,000, with a deadline of completion of December 2023. No accounting entries nor payments were made towards this grant during the year.

Lastly, post year end in July 2021 a grant was offered to Annie Gao within the Bob Champion Unit, Royal Marsden Hospital. The agreed funding is £42,000 for 3 years (including standard on-costs) to commence not before 1st September 2021. No accounting entries nor payments were made towards this grant during the year.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

7. Analysis of expenditure by activities

	Grant funding of activities 2021 £	Support costs 2021 £	Total funds 2021 £	Total funds 2020 £
Premises costs	-	13,453	13,453	13,142
Other costs	-	15,077	15,077	9,232
Personnel costs	-	62,929	62,929	71,319
Governance costs	-	13,123	13,123	9,840
Professor Rosalind Eeles grant - Institute of Cancer Research	92,710	-	92,710	23,056
Dr. Gert Attard grant - ICR and UCL	55,125	-	55,125	28,030
Professor Colin Cooper grant - UEA	39,387	-	39,387	33,139
Total	187,222	104,582	291,804	187,758

8. Staff costs

	2021 £	2020 £
Wages and salaries	58,920	65,478
Social security costs	2,241	3,909
Contribution to defined contribution pension schemes	1,768	1,932
	62,929	71,319

The average number of persons employed by the charity during the year was as follows:

	2021 No.	2020 No.
Employees	2	2

No employee received remuneration amounting to more than £60,000 in either year.

The total employment benefits of key management personnel were £50,520 (2020 - £50,520).

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

9. Tangible fixed assets

	Computer equipment £
Cost or valuation	
At 1 July 2020	6,782
At 30 June 2021	<u>6,782</u>
Depreciation	
At 1 July 2020	3,514
Charge for the Year	816
At 30 June 2021	<u>4,330</u>
Net book value	
At 30 June 2021	<u><u>2,452</u></u>
At 30 June 2020	<u><u>3,268</u></u>

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

10. Fixed asset investments

	Investments in subsidiary companies £	Listed investments £	Total £
Cost or valuation			
At 1 July 2020	2	1,448,747	1,448,749
Revaluations	-	215,043	215,043
At 30 June 2021	<u>2</u>	<u>1,663,790</u>	<u>1,663,792</u>
Net book value			
At 30 June 2021	<u>2</u>	<u>1,663,790</u>	<u>1,663,792</u>
At 30 June 2020	<u>2</u>	<u>1,448,747</u>	<u>1,448,749</u>

Subsidiary undertakings

The following was a subsidiary undertaking of the charity:

Name	Holding
Aldaniti Trading Company Limited	100%

The financial results of the subsidiary for the year were:

Name	Aggregate of share capital and reserves £
Aldaniti Trading Company Limited	2

At 30 June 2021, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,663,790 (2020 - £1,448,747). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain is included in the statement of financial activities.

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

BOB CHAMPION CANCER TRUST

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

11. Debtors

	2021	2020
	£	£
Due within one year		
Other debtors	10	4,998
Prepayments and accrued income	1,318	1,676
	1,328	6,674

12. Creditors: Amounts falling due within one year

	2021	2020
	£	£
Creditors	1,419	959
Creditors - ICR and UEA grants	37,324	11,366
Amounts owed to group undertakings	2	2
Other taxation and social security	9	2,598
Other creditors	355	272
Accruals and deferred income	19,314	17,318
Accruals - UEA grants	9,870	9,521
	68,293	42,036

13. Financial instruments

	2021	2020
	£	£
Financial assets		
Financial assets measured at fair value through income and expenditure	1,663,790	1,448,747

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021**

14. Pension commitments

The charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,768 (2020 - £1,932). Contributions totalling £233 (2020 - £272) were payable to the fund at the balance sheet date and are included in creditors.

15. Related party transactions

During the year, the charity paid £25,680 (2020 - £28,630) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £6,200 (2020 - £4,960). Bob Champion's retainer has been approved by the Charity Commission. Bob Champion took a 20% cut to his retainer for the lockdown period as support for the cause.